Stockreport

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF ? Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ? ? Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ? ? Raising FY 2025 Pro Forma [Read more]